Tags

  • Search

  • Sorting

  • Filters

Using the X500R QTOF System and SCIEX OS to Identify and Quantify Food Residues

by | 0 Comments

Farmers use pesticides to protect crops from insects and disease as pesticides are necessary to create the volume of food that our population requires. Without them, we would not be able to grow enough crops to feed the world—they are a necessary evil. Government agencies such the Food and Drug Administration (FDA) in the United States and pesticide manufacturers, however, work hard to educate farmers on how to minimize their use. However, sometimes farmers add too much which leaves a residue. Upon harvest, farmers wash the fruit and vegetables. Once complete the crop then makes its way to the wholesaler and eventually, the supermarket. Even so, there may still be pesticide residue on the produce, which is why government agencies randomly pull produce from store shelves for testing of maximum residual limits (MRLs) and we are encouraged to wash our food before consuming it

The World Has its Eyes on Precision Medicine

by | 0 Comments

What if we could understand and then treat diseases on an individualized level, in a way that was tuned to a person’s individual biology? Not in a futuristic, ‘wave a high-tech scanner across a person’s body’ way, but in a legitimate ’I can run a lab test and know the best action to take’ way. This is the promise of Precision Medicine, to deliver the right treatment to the right patient, at the right time, predicting more accurately which treatments will work for certain groups of patients, in contrast to the pervasive one-size-fits-all approach. More specifically, if we could provide a comprehensive report at the molecular level of an individual (based on genome, proteome, or metabolome profiles), a physician could be much better informed to make optimal treatment decisions. And if we could track these profiles over time, a person could adjust their lifestyle to focus on long-term wellness.

Setting Records with Fast Glycan Technology

by | 0 Comments

There is a lot of talk going around in the lab, and it has to do with the newly released Fast Glycan Labeling and Analysis technology. Where once research analysts needed to set aside days to perform glycan analysis, now takes an hour or so. Glycans are immediately identified by the software – so no need for data interpretation. That’s up to 5x faster than HILIC.

Overcoming uncertainty in your PFAS analysis

Overcoming uncertainty in your PFAS analysis

by | ,

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

6 Signs it’s time for a new vendor

6 Signs it’s time for a new vendor

by | , , ,

A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.

Nitrosamines: Where are we now?

Nitrosamines: Where are we now?

by | , ,

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

by | ,

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SCIEX Now™ support network
The destination for all your support needs.
Contact support
Wordpress Social Share Plugin powered by Ultimatelysocial